Mitoxantrone: all 172 studies that test it

Page 1 of 2. Open to participants first (22), then studies with results posted, then the rest; newest registration first within each.

• Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingNCT07831395Phase 2
• Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AMLRecruitingNCT07490288Not applicable
• Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCLNot yet recruitingNCT07389356Not applicable
• Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer SurgeryNot yet recruitingNCT07354698Phase 4
• Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)Not yet recruitingNCT07288814Phase 1/2
• MRD-positive AML Clinical StudyRecruitingNCT07131059Not applicable
• JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal CancerNot yet recruitingNCT06892431Phase 2
• Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.RecruitingNCT06514313Phase 2
• VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCTRecruitingNCT06447090Phase 2
• Mitoxantrone for Venetoclax Resistant Acute Myeloid LeukemiaRecruitingNCT06429449Phase 1
• Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AMLNot yet recruitingNCT06385808Not applicable
• Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNCT06265545Not applicable
• Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLRecruitingNCT06221683Phase 2
• The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.Not yet recruitingNCT05990985Not applicable
• Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell LymphomaRecruitingNCT05958719Phase 2
• Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)RecruitingNCT05875428Phase 2
• Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT05857982Phase 1/2
• TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIRecruitingNCT05848687Phase 1/2
• Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid LeukemiaRecruitingNCT05522192Phase 1/2
• Treateament of Newly Diagnosed Acute Monocytic Leukemia in ChildrenRecruitingNCT05313958Phase 2/3
• Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsRecruitingNCT04797767Phase 1/2
• CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaRecruitingNCT04375631Phase 1
• CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit PatientsCompletedNCT04195945Phase 2Results posted
• Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction TherapyCompletedNCT03839446Phase 2Results posted
• Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid NeoplasmCompletedNCT03531918Phase 1/2Results posted
• Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AMLTerminatedNCT03504410Phase 3Results posted
• Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03118466Phase 2Results posted
• Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid NeoplasmCompletedNCT03012672Phase 2Results posted
• Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDSCompletedNCT02921061Phase 1/2Results posted
• Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid NeoplasmsCompletedNCT02756572Phase 2Results posted
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02728050Phase 1/2Results posted
• Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT02583893Phase 2Results posted
• Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) IActive, not recruitingNCT02553460Phase 1/2Results posted
• Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young AdultsTerminatedNCT02535806Phase 2Results posted
• Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down SyndromeActive, not recruitingNCT02521493Phase 3Results posted
• CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic SarcomaCompletedNCT02484391Phase 1Results posted
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT02044796Phase 1/2Results posted
• Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT01729845Phase 1/2Results posted
• Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01371981Phase 3Results posted
• Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01349972Phase 2Results posted
• Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01342887Phase 1/2Results posted
• Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)CompletedNCT01184898Not applicableResults posted
• R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical TrialCompletedNCT01133158Phase 2Results posted
• Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular LymphomaTerminatedNCT00901927Phase 2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00795002Phase 2Results posted
• High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AMLCompletedNCT00774046Phase 2Results posted
• Ph2 Gem/Nov/Rituxan Rel/Ref MantleCellCompletedNCT00656084Phase 2Results posted
• Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00634244Phase 2Results posted
• Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell TransplantationTerminatedNCT00609739Phase 1/2Results posted
• Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell CancerCompletedNCT00546377Phase 1/2Results posted
• AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid LeukemiaCompletedNCT00512252Phase 1/2Results posted
• Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular LymphomaTerminatedNCT00510887Phase 2Results posted
• Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate CancerTerminatedNCT00477087Phase 2Results posted
• Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)TerminatedNCT00452387Phase 2Results posted
• Study of VELCADE® With Mitoxantrone and Etoposide for LeukemiasCompletedNCT00410423Phase 1/2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00407966Phase 2Results posted
• Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and ChemotherapyCompletedNCT00331344Phase 1/2Results posted
• Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular LymphomaCompletedNCT00290511Phase 2Results posted
• Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid LeukemiaTerminatedNCT00268242Phase 2Results posted
• FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 YearsCompletedNCT00254410Phase 2Results posted
• Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and RituximabTerminatedNCT00208975Phase 2Results posted
• Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT00186875Phase 2Results posted
• Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or MyelodysplasiaCompletedNCT00136084Phase 3Results posted
• S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00109837Phase 2Results posted
• Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate CancerCompletedNCT00017563Phase 2Results posted
• S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate CancerCompletedNCT00004124Phase 3Results posted
• Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or LymphomaCompletedNCT00002766Phase 3Results posted
• R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05784987Not applicable
• R-CMOP in Patients With Primary Diffuse Large B-cell LymphomaStatus unknownNCT05777369Not applicable
• Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid TumorsActive, not recruitingNCT05620862Phase 1
• Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)CompletedNCT05551598Phase 2
• A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple SclerosisWithdrawnNCT05496894Phase 2
• A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid LeukemiaTerminatedNCT05345938Phase 1/2
• GM-CLAG in Relapsed/Refractory FLT3-mutated AMLWithdrawnNCT05330377Phase 1
• Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma SubjectsCompletedNCT05173545Phase 1
• A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic CancerStatus unknownNCT05100329Phase 2
• A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant TumorSuspendedNCT05089461Phase 2
• A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast CancerTerminatedNCT04927481Phase 2
• A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid TumorsCompletedNCT04921878Phase 1
• A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck CancersCompletedNCT04902027Phase 1
• A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue SarcomaTerminatedNCT04900766Phase 1
• A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid TumorStatus unknownNCT04719065Phase 1
• A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric CarcinomaTerminatedNCT04718402Phase 1
• A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian CancerTerminatedNCT04718376Phase 1
• Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCLActive, not recruitingNCT04668690Phase 3
• Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCLTerminatedNCT04548700Phase 1
• Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCLTerminatedNCT04509466Phase 1/2
• A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line ChemotherapyTerminatedNCT04352413Phase 2
• A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCCStatus unknownNCT04331743Phase 1
• Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid NeoplasmsTerminatedNCT04196010Phase 1
• Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT03983824Phase 1
• A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell LymphomaStatus unknownNCT03776279Phase 2
• Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
• A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid LeukemiaCompletedNCT03563560Phase 1
• PLM60 for Peripheral T Cell Lymphoma (PTCL)WithdrawnNCT03553914Phase 1/2
• Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03441048Phase 1
• National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple SclerosisCompletedNCT02937285Phase 3
• A Study of Mitoxantrone Hydrochloride Liposome InfusionStatus unknownNCT02856685Phase 1/2
• Optimal Treatment Strategy Based on for Pediatric AMLStatus unknownNCT02848183Phase 2
• Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous LeukemiaTerminatedNCT02631252Phase 1

← Mitoxantrone overview